Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Australia
  4. Australian Stock Exchange
  5. Immutep Limited
  6. News
  7. Most relevant
    IMM   AU000000IMM6

IMMUTEP LIMITED

(IMM)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news
Most relevant news about IMMUTEP LIMITED
09/27IMMUTEP : to Present at Healthcare Investor Conferences
PU
09/21Immutep to Present Final Overall Survival Data FromáPhase IIb AIPAC as a Late Breaking ..
GL
09/21Immutep to Present Final Overall Survival Data from Phase IIb AIPAC as a Late Breaking ..
CI
09/20IMMUTEP : Maxim Group - The Case for LAG-3 is Building
PU
09/20IMMUTEP : ESMO 2021 – INSIGHT - Stratum D Poster
PU
09/20IMMUTEP LIMITED(NASDAQGM : IMMP) added to S&P Global BMI Index
CI
09/02IMMUTEP : Completes Recruitment of 2nd line PD-1/PD-L1 refractory NSCLC Patients in TACTI-..
PU
09/01IMMUTEP : Completes Patient Enrollment in Stage 2 of Part B of NSCLC Study; Shares Drop Ea..
MT
09/01IMMUTEP : PRELIMINARY FINAL REPORT (Form 6-K)
PU
09/01IMMUTEP : Completes Recruitment, Dosing in Phase 2 Trial of Non-Small Cell Lung Cancer Com..
MT
09/01IMMUTEP : Completes Recruitment of 2nd line PD-1/PD-L1 refractory NSCLC Patients in TACTI-..
PU
08/31Immutep Limited Announces Recruitment of Patients Completed for Part B of TACTI-002
CI
08/31IMMUTEP : Chinese Partner, Eoc Pharma, Expands Efti Trial Pipeline
AQ
08/31IMMUTEP : Chinese Partner to Expand Clinical Trial Pipeline for Cancer Drug
MT
08/31IMMUTEP : S CHINESE PARTNER, EOC PHARMA, EXPANDS EFTI TRIAL PIPELINE (Form 6-K)
PU
08/30IMMUTEP : Partner, EOC Pharma, Expands Efti Trial Pipeline
PU
08/30IMMUTEP : Maxim Group - Annual FY Update; AIPAC Final Data Approaching
PU
08/30Immutep Limited Reports Earnings Results for the Full Year Ended June 30, 2021
CI
08/27ADRs End Higher, Immutep and BioNTech Among Companies Actively Trading
DJ
08/27IMMUTEP : ANNOUNCES CHINESE PATENT GRANT FOR LAG-3 ANTAGONIST ANTIBODY LAG525 (Form 6-K)
PU
08/27IMMUTEP : Receives Chinese Patent for LAG-3 Antagonist Antibody LAG525
MT
08/27IMMUTEP : Secures Chinese Patent for Antagonist Antibody
MT
08/26IMMUTEP : Announces Chinese Patent Grant for LAG-3 Antagonist Antibody LAG525
PU
08/05IMMUTEP : Reports Dosing of First Patient for Triple Combination (efti + anti-PD-1 + chemo..
AQ
08/05Immutep Limited Reports Dosing of First Patient for Triple Combination (efti + anti-PD-..
CI
08/05IMMUTEP : Reports Dosing of First Patient For Triple Combination (efti + anti-PD-1 + chemo..
PU
08/04IMMUTEP : Doses First Patient with Efti-Combination to Treat Tumors
MT
08/04IMMUTEP : INSIGHT-003 investigator-initiated trial - 1st patient dosed
PU
08/03IMMUTEP : Ladenburg Thalman - New Age Immune Regulator; Initiate with a Buy Rating and $8...
PU
08/03IMMUTEP : Ladenburg Thalmann Starts Immutep at Buy With $8.30 Price Target
MT
08/02IMMUTEP : completes tranche 2 of its previously announced placement (Form 6-K)
PU
07/29IMMUTEP : Completion of Placement - Tranche 2
PU
07/26IMMUTEP : Results of EGM
PU
07/25IMMUTEP : 2021 EGM Presentation
PU
07/21IMMUTEP : Raises over $5 Million in Share Purchase Plan
MT
07/20IMMUTEP : Completion of Share Purchase Plan
PU
07/16IMMUTEP : Maxim Group - Unlocking the Synergistic Benefits of Efti (LAG-3), the Next Check..
PU
07/15IMMUTEP : Non-Small Cell Lung Cancer (NSCLC) Drug Development Summit - poster presentation
PU
07/14IMMUTEP : Quarterly Activities Report & Appendix 4C (Form 6-K)
PU
07/13IMMUTEP : Bell Potter - Creating Value with Phase 3 around the corner – Increasing T..
PU
07/13IMMUTEP : Quarterly Activities Report
AQ
07/13Immutep Limited Provides an Update on the Ongoing Development of Its Product Candidates
CI
07/06IMMUTEP : Australia's Immutep Gets US Regulatory Nod to Start Mid-Stage Trial in Head and ..
MT
07/06IMMUTEP : receives FDA and IRB approval in the US for Phase IIb TACTI-003 trial in HNSCC
AQ
07/05Immutep Receives FDA and IRB Approval in the US for Phase IIb TACTI-003 Trial in HNSCC
CI
06/22IMMUTEP : completes a A$60 million placement to expand its clinical development and manufa..
PU
06/22IMMUTEP : to Evaluate Efti in Triple Combination Therapy Phase I Study with Chemotherapy a..
PU
06/21ADRs End Mostly Higher, 51job, SOS, Immutep Trade Actively
DJ
06/21IMMUTEP : to Launch Early-Stage Study to Test Combination Solid Tumor Therapy
MT
06/21Wall Street Set for Rebound After Fed Fallout
MT
06/21IMMUTEP : Conducts $45 Million Placement to Finance Expansion of its Clinical Development,..
MT
06/21IMMUTEP : Completes a A$60 Million Placement to Expand its Clinical Development and Manufa..
AQ
06/21IMMUTEP : to Evaluate Cancer Drug Eftilagimod Alpha; Shares Plunge 12%
MT
06/21Immutep Limited announced that it expects to receive AUD 60 million in funding
CI
06/20IMMUTEP : Raises $45 Million to Advance Clinical Development, Manufacturing Program; Share..
MT
06/20IMMUTEP : Capital Raising Presentation
PU
06/20IMMUTEP : secures commitments for A$60 million through a two-tranche institutional placeme..
PU
06/20IMMUTEP : to Evaluate Efti in Triple Combination Therapy Phase I Study with Chemotherapy a..
PU
06/20Immutep Limited Signs Agreement to Commence New Phase I Trial, Called Insight-003, to E..
CI
06/10IMMUTEP : Alliance Global Partners - Immutep's Vindication and the Next Chapter in LAG-3 I..
PU
06/09IMMUTEP : TACTI-002 and INSIGHT Clinical Results & Update Global Webcast Slides
PU
06/09IMMUTEP : Reveals a New anti-LAG-3 Research Program (Form 6-K)
PU
06/07IMMUTEP : Reveals New Research Program on Anti-LAG-3 Therapies Under Collaboration Project..
MT
06/07IMMUTEP : Reveals a New anti-LAG-3 Research Program
PU
06/07Immutep Limited Reveals a New anti-LAG-3 Research Program
CI
06/07IMMUTEP : Reports Positive Final Data from the INSIGHT-004 Phase I Study of LAG-3 Therapy,..
PU
06/07IMMUTEP : Reports Positive Data from its TACTI-002 Phase II Study of LAG-3 Therapy, Efti, ..
PU
06/05IMMUTEP : Goetzpartners securities - Efti combos move towards centre stage at ASCO
PU
06/04IMMUTEP : Maxim Group - ASCO Updates, LAG-3 is Emerging – Shares RemainUndervalued
PU
06/04IMMUTEP : ASCO 2021 - TACTI-002 Poster for NSCLC
PU
06/04IMMUTEP : ASCO 2021 - TACTI-002 Poster for HNSCC
PU
06/04IMMUTEP : ASCO 2021 - INSIGHT Poster
PU
06/04IMMUTEP : Reports Positive Data From Study of Lead Candidate Eftilagimod Alpha; Shares Ris..
MT
06/04IMMUTEP : Reports Positive Final Data from the INSIGHT-004 Phase I Study of LAG-3 Therapy,..
AQ
06/04Immutep Reports Positive Data from its TACTI-002 Phase II Study of LAG-3 Therapy, Efti,..
GL
1  2  3  4  5  6  7Next
Upcoming event on IMMUTEP LIMITED